Highlights : IFFCO and Mitsubishi Corporation formed a joint venture to produce Tabiki (Flubendiamide 20% WG). The major causes of biotic stress…
ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved.
Designed and Developed by Ample eBusiness
-
-
AstraZeneca today announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing…
-
442 RC meetingCIBRC - Indian Pesticide ApprovalsIndiaRC Meeting updates
INDIAN PESTICIDE APPROVALS – 442ND RC MEETING – CHLORANTRANILIPROLE – FMC MOLECULE – MAJOR HIGHLIGHT
INDIAN PESTICIDE APPROVALS UPDATES – MINUTES OF THE 442ND REGISTRATION COMMITTEE (RC) MEETING HELD ON 18.11.2022 The 442nd meeting of the Registration…
-
RegulatoryU.S FDA
FDA Approves First-in-Class Microbiota-Based Live Biotherapeutic for C. Difficile Infection
Summary- The FDA has approved fecal microbiota, live-jslm (Rebyota; Ferring Pharmaceuticals) for the prevention of recurring Clostridioides difficile infection (CDI) among patients 18…
-
ChemRobotics and AgbioInvestor are happy to announce the establishment of a new international partnership utilising the pharmacological intelligence platform of ChemRobotics. AgbioInvestor…
-
RegulatoryU.S FDA
The FDA has Approved TZIELDTM (Teplizumab-mzwv) as the First and Only Medication Intended to Postpone the onset of Stage 3 Type 1 Diabetes (T1D) in Adult and Paediatric Patients with Stage 2 T1D Who are 8 Years of Age and Older.
Summary:- TZIELD is the first disease-modifying therapy in T1D, a life-threatening autoimmune disease In a clinical trial, in Stage 2 T1D patients,…
-
RegulatoryU.S FDA
Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)
Summary: Approval based on superior survival outcomes of Libtayo plus chemotherapy, compared to chemotherapy alone, in a patient population with a wide…
-
CompaniesPfizerRegulatoryU.S FDA
Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for relapsed or Refractory Multiple Myeloma
Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for…
-
RegulatoryU.S FDA
U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Summary-The Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), the first bispecific B-cell maturation antigen (BCMA)-directed CD3…
-
GskMerger / Acquisition
To Speed up R&D, GSK Announces an Expanded Partnership with Tempus in Precision Medicine.
GSK plc (LSE/NYSE: GSK) and Tempus, a US-based precision medicine company, have entered into a three-year collaboration agreement that provides GSK with…